MBX Biosciences, Inc. 8-K

What Happened
MBX Biosciences (MBX) filed an 8‑K reporting that CEO Kent P. Hawryluk will step down as CEO and leave the Board effective July 13, 2026. Hawryluk will provide transition and strategic consulting through August 16, 2026; his departure is not due to any dispute with the company or auditors. The Board appointed Executive Chairman Steven Hoerter as President and CEO and promoted interim CFO John Smither to Chief Financial Officer, both effective July 13, 2026. Employment agreements were signed for Hoerter (July 10, 2026) and Smither (July 11, 2026); details of the agreements and separation/consulting arrangements will be filed in MBX’s next Form 10‑Q.

Key Details

• CEO departure package: Hawryluk is entitled to 12 months of base salary as severance, up to 12 months of company‑paid COBRA, a cash bonus equal to his target annual bonus, accelerated vesting of time‑based awards through August 16, 2027, and an extended post‑termination option exercise period until July 13, 2027, subject to customary post‑employment covenants.
• New CEO (Steven Hoerter): base salary $665,000, target annual bonus 60%; equity to be granted Aug 3, 2026 — 331,000 stock options and 71,000 RSUs. Options vest 25% after 1 year then monthly over 36 months; RSUs vest 25% each year over 4 years.
• New CFO (John Smither): base salary $530,000, target annual bonus 40%; one‑time $150,000 relocation bonus (50% within 30 days, 50% by Jan 15, 2027); equity to be granted Aug 3, 2026 — 130,000 options and 28,000 RSUs with similar vesting. Option exercise price for Smither will equal the closing stock price on the grant date.
• Hawryluk will consult on an as‑needed basis through Aug 16, 2026; if the company terminates his consulting without cause during that period, certain outstanding awards will immediately vest for the portion that would have vested through Aug 16, 2026.

Why It Matters
This filing documents a leadership transition at MBX with its chairman stepping into the CEO role and the interim CFO becoming permanent — changes that affect corporate strategy and management continuity. The disclosed severance, consulting arrangement and accelerated/extended vesting terms create near‑term compensation and potential expense items, while the sizable option and RSU grants for the new CEO and CFO represent potential future share dilution. Investors should watch upcoming filings (the Form 10‑Q) for the full agreements and any additional disclosure.